Celex Oncology Announce Novel Mechanism in Cancer Care and Attendance at Bio-Europe Spring 2025
LONDON, March 17, 2025 (GLOBE NEWSWIRE) -- Celex Oncology, a UK biotechnology company founded in 2017 and on the brink of launching the fourth revolution in cancer care, today announced the Celex model and investigative treatment. The treatment* has the potential to control metastatic cancer and block the processes that lead to advanced metastatic disease, which is responsible for approximately 90% of all cancer deaths globally.1
Despite advances in oncology, the aggressive nature of many cancers continues to pose significant challenges, with unresolved disease progression, treatment-induced side-effects and resistance to treatment remaining key issues.2 To date, three major paradigms have existed in cancer care with Celex Oncology proposing a new paradigm: targeting sodium overload in tumour cells*.
Several recent research papers stress the importance of the understanding of the bioelectricity of cancer for treatments3 and the involvement of voltage-gated sodium channels (VGSCs) in progression and metastasis.4 This research underscores its significance as a potential novel therapeutic target. Celex Oncology is investigating VGSC inhibitors which have the potential to reverse cancer progression and harness the power of bioelectricity, reversing and blocking the processes that lead to advanced and deadly oncological disease.
Celex Oncology is in attendance at the Bio-Europe Spring 2025 scientific congress (17th – 19th March) in Milan, Italy, where leadership will be meeting with investors, pharma & biotech companies and industry experts to discuss their technology and investigational plan.
Celex Oncology's first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult programme, which recognises and awards the highest-potential life science and health tech start-ups. Celex Oncology took home the Life Science award in their potential treatment for invasive and metastatic cancer.5
'At Celex Oncology, we are steadfast in our determination to deliver an alternative option for patients with metastatic cancer. We have spent years deepening our understanding of cancer invasion and progression. In addition to our VGSC inhibitors we are developing tumour specific monoclonal antibodies (mAb) to target a key protein present in invasive breast and colon cancer. This has been undertaken by identifying a special version of a tissue protein that appears in tumours and aids in metastasis,' said Dr Sara Moodad, Vice President of Research & Development, Celex Oncology. 'We are advancing rapidly towards clinical trials, aiming to significantly improve both survival and quality of life, with a therapeutic option complementary to existing treatments.'
Carsten Faltum, CEO, Celex Oncology, said, 'We're delighted to be at Bio-Europe Spring 2025 alongside other life science and biotech leaders. We are here to continue our journey of bringing new solutions to long-term and unresolved issues in cancer care. Our investigational treatments are designed to control tumours and thereby improve survival. They have the potential to be transformative and could change metastatic cancer care by turning it from a life-threatening disease into a controlled and treatable long-term condition. We are looking forward to discussions about Celex Oncology and our goals, which will empower clinicians and could lead to a future where cancer is no longer synonymous with inevitable decline but instead a controllable condition that allows a person living with cancer to lead a longer, more active, more productive life.'
While VGSC inhibitors will need to undergo further testing to realise their clinical potential, the possibility of managing metastatic cancer in a non-toxic and cost-effective way is promising and 'should be welcomed by cancer patients and clinicians'.4
Notes for Editors
Fact Box
Celex Oncology is harnessing the power of bioelectricity, targeting voltage-gated sodium channels (VGSCs) to reverse cancer cell aggression and block the processes that lead to advanced oncological disease The drug will be a daily, oral pill that restores normal intracellular sodium level.
Sodium is one of the most crucial and fundamental cell components with a key role in regulation of many vital cell processes and tumour cell behaviour.
This novel mechanism of action and new target is supported by robust preclinical data and real-world evidence (RWE) in several indications demonstrating a significant pan-cancer opportunity.
Founded in 2017, Celex Oncology is transforming cancer care by turning it from a life-threatening disease into a controlled and treatable long-term condition.
The first-in-class, proprietary treatment will target sodium overload in tumour cells – one of the most crucial cell components and key regulators of tumour cell behaviour. Sodium is one of the most crucial and fundamental cell components with a key role in regulation of many vital cell processes and tumour cell behaviour.
Celex Oncology's CL-S01 and CL-S03 treatments*, still in investigational stage, aim to improve both survival and quality of life. Designed for rapid integration into existing clinical regiments, the cost-effective and easy-to-administer approach could redefine the future of cancer care.
The strong business model is centred around four separate but inter-linked areas within the product profile: tumour treatment, monoclonal antibodies, diagnostic and cardiac protection.
Follow Celex Oncology's journey on LinkedIn
Contact Details
Stephanie Harris, Associate Director, MD Health Communicationsstephanie.harris@mdhealthcomms.com +44 (0)7590562038
References
Hudock, N.L. et al. (2023) 'Future trends in incidence and long-term survival of metastatic cancer in the United States', Communications Medicine, 3(1), pp. 1–7. Available at: https://doi.org/10.1038/s43856-023-00304-x
Mayo Clinic Staff (2022) Managing the lingering side effects of cancer treatment, Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-survivor/art-20045524. Last accessed March 2025.
Pukkanasut, P. et al. (2024) 'Therapeutic targeting of voltage-gated sodium channel NaV1.7 for cancer metastasis', Frontiers in Pharmacology, 15. Available at: https://doi.org/10.3389/fphar.2024.1416705
Djamgoz, M.B.A. (2024) 'Electrical excitability of cancer cells—CELEX model updated', Cancer and Metastasis Reviews, 43(4), pp. 1579–1591. Available at: https://doi.org/10.1007/s10555-024-10195-6
Europe's next generation of elite health innovation start-ups recognised - EIT Health (2024) EIT Health. Available at: https://eithealth.eu/news-article/europes-next-generation-of-elite-health-innovation-start-ups-recognised/ Last accessed March 2025.
* Investigational treatment only, not approved for use
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c011931-0343-4c0d-bb26-c4a511d38164
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
XRP Price Consolidates for 200 Days, PFMCrypto Launches XRP Mining Contract to Unlock a New Profit Model for XRP
Farington, England, June 20, 2025 (GLOBE NEWSWIRE) — What Is PFMCrypto XRP Cloud Mining? PFMCrypto cloud mining is a remote digital asset mining platform that enables users to earn cryptocurrency by renting computing power from PFMCrypto's eco-friendly, high-performance mining farms. Supporting a broad array of coins—including XRP, DOGE, BTC, LTC, SOL, etc. —PFMCrypto removes the technical and financial obstacles traditionally associated with crypto mining, making passive income more accessible than ever. Check the official website for details: Key Highlights of the XRP Cloud Mining Contract: – Strategic Launch Timing: The contract was launched during a period of XRP price consolidation, offering investors a way to profit regardless of short-term market moves. – Stable Passive Returns: PFMCrypto's new XRP contract provides fixed daily payouts with guaranteed principal return, appealing to both traders and long-term holders. – No Technical Barriers: The XRP mining model requires no hardware or maintenance—any user can participate instantly. New Profit Model: XRP Mining Meets AI Optimization PFMCrypto's AI-powered mining architecture now supports XRP-specific contracts, leveraging intelligent allocation of hash power to maximize yields while reducing risk. This model is especially timely, given that XRP has traded in a narrow band for months, signaling the perfect moment for alternative yield strategies. Rather than waiting for a price breakout, PFMCrypto users can now earn XRP daily through smart mining contracts—without buying more tokens or attempting to time the market. Why This XRP Mining Contract Stands Out? – 100% Remote Access: No rigs, no tech know-how—just log in and activate a plan. – Principal Security: Contract terms guarantee full capital return after expiration. – AI-Driven Returns: Yield optimization ensures users earn even during price stagnation. – Daily Earnings: Predictable XRP payouts improve cash flow and reduce volatility exposure. Join PFMCrypto and receive a $10 sign-up bonus to begin XRP mining immediately. PFMCrypto's CEO commented, 'We view XRP's consolidation not as stagnation, but as opportunity. Our new mining contract allows the XRP community to unlock value from this asset in a consistent, low-risk way.' Proven Mining Models for XRP Investors PFMCrypto's XRP mining contracts have already shown strong user interest across multiple tiers. Sample return rates include: 2-Day Plan: +6.0% return and $2 Bonus 5-Day Plan: +6.15% return 15-Day Plan: +20.7% return 30-Day Plan: +47.1% return These results are based on historical contract data and reflect PFMCrypto's commitment to transparency and performance. How to Start Mining XRP with PFMCrypto Sign Up: New users receive a $10 welcome bonus and $0.60 daily login rewards. Select a Contract: Choose from flexible XRP mining durations to match your investment goals. Start Earning: PFMCrypto's AI-driven engine takes care of the rest—earning begins immediately upon activation. About PFMCrypto Founded in 2018, PFMCrypto is a leading provider of AI-powered cloud mining services. With over 9.2 million users in 190+ countries, the platform has paid out more than $1 billion in crypto rewards. Its offerings span BTC, LTC, XRP, DOGE, and more—enabling secure, hardware-free mining experiences backed by top-tier infrastructure. Explore the future of XRP mining at Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
3 hours ago
- Business Upturn
Cost-Saving Air Filtration for Ontario Schools: Expert Insights from Camfil Canada Air Quality Specialist Joshua Guthrie
Toronto, ON, June 20, 2025 (GLOBE NEWSWIRE) — Indoor air quality (IAQ) plays a crucial role in creating a healthy and productive learning environment for students and staff in Ontario schools. Camfil Canada has launched a new article and accompanying video focusing on how schools in Ontario can save money on air filtration costs while improving indoor air quality. The resources are designed to help school boards and administrators tackle rising operational costs in a practical, effective way. The article, How Canadian Schools Can Save Money and Create Healthier Learning Environments , highlights the growing financial pressures faced by Canadian schools and introduces innovative ways to cut expenses related to HVAC systems and air filter maintenance. The video further supports this message by detailing real-world examples of cost-saving strategies implemented in Ontario schools, including the use of advanced air filters with high dust-holding capacities and energy-efficient designs. 'As school boards across Canada face funding pressures and seek to decrease operational costs, they could be overlooking an expense that could achieve significant savings for schools,' said Joshua Guthrie, Life Science Segment Leader and NAFA Certified Air Filtration Specialist at Camfil Canada, 'The type of air filter used could be costing Canadian schools far too much in terms of energy consumption, labour for changeouts and maintenance, and filter replacement costs.' Key topics covered include how premium filters can extend service life, reduce waste, lower energy consumption, and decrease overall HVAC system strain. Notably, Camfil Canada's team emphasizes on-site testing and Life Cycle Cost analysis (LCC) as essential tools for tailoring filtration solutions to a specific school's needs. The article also sheds light on the impressive results achieved by some Ontario school boards, where transitioning to advanced filtration systems resulted in reduced filter replacement costs and significant energy savings. One Ontario school board, for instance, saved over $500,000 in filter costs alone by adopting Camfil's air filter solutions. To learn more about how school districts can save on energy costs while improving air quality in Ontario schools, read Camfil Canada's full article and watch the accompanying video. To access these resources, see the article at Camfil Canada or watch the full video on YouTube here. About Camfil Canada For more than 60 years, Camfil has been helping people breathe cleaner air. As a leading manufacturer of premium clean air solutions, we provide commercial and industrial systems for air filtration and air pollution control that improve worker and equipment productivity, minimize energy use, and benefit human health and the environment. Media Contact: Phillip Ilijevski Phone: 437-929-1161 Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
3 hours ago
- Business Upturn
Media Advisory: Astro Yogurt Brand Unveils 'So Canadian' Flyover Welcome Message for Toronto Pearson International Airport Arriving Passengers, Ahead of Canada Day
By GlobeNewswire Published on June 20, 2025, 22:48 IST TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — On Monday, June 23, 2025, media are invited to attend a special event at Lactalis Canada's yogurt processing facility in Etobicoke, Ontario as part of its iconic Astro yogurt brand's bold new 'So Canadian' campaign in the lead up to Canada Day. WHAT: The unveiling of a special rooftop mural at Astro's processing facility adjacent to and on the flight path of Toronto Pearson International Airport. The uniquely Canadian rooftop mural will be visible to passengers flying into the Toronto airport, reflecting the kind, warm and inclusive identity that defines Canadians. The event will also include remarks from Lactalis Canada President & CEO Mark Taylor and other company executives, government and community partners, a photo opportunity with a giant Astro yogurt tub and Canadian-inspired festivities. WHEN: Monday, June 23, 2025 • Media Registration: 10:30 a.m. • Opening Ceremony: 11:00 a.m. to 11:30 a.m. • Photo Opportunity: 11:35 a.m. Media are encouraged to arrive at 10:30 a.m. for registration. Media accreditation required. WHERE: Lactalis Canada Rakely Plant, 25 Rakely Ct, Etobicoke, ON M9C 5G2 PHOTO OP: Following the ceremony and photo opportunity, media will have the chance to conduct 1:1 interviews with speakers. About Lactalis Canada Inc. With over 140 years of brand heritage, Lactalis Canada is the Canadian dairy leader behind iconic brands Cracker Barrel, Black Diamond, P'tit Québec, Balderson, Cheestrings Ficello, aMOOza!, Astro, Khaas, siggi's, IÖGO, IÖGO nanö, Olympic, Lactantia, Beatrice, Bfit, Enjoy!, Marie Morin Canada, Galbani, and Président. With more than 30 operating sites including 20 manufacturing facilities across Canada, the company and its more than 4000 employees are committed to enriching and nurturing the lives of Canadians through sustainable and responsible growth, high-quality products, contribution to communities and partnership with farmers, customers, partners and suppliers. Lactalis Canada has been named on Forbes' 2025 Best Employers in Canada and one of Greater Toronto's Top Employers for 2025. The company is part of Lactalis Group, the world's leading dairy company, headquartered in Laval, France. For more information, visit Media Contact: Lactalis Canada Media Relations [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
